Status:
UNKNOWN
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Lead Sponsor:
Introgen Therapeutics
Collaborating Sponsors:
M.D. Anderson Cancer Center
Conditions:
Malignant Melanoma
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.
Detailed Description
INGN 241 is an adenoviral vector carrying the MDA-7 cDNA. MDA-7 is a novel tumor suppressor molecule with cytokine properties, recently designated as IL-24. Over expression of MDA-7 in melanoma cells ...
Eligibility Criteria
Inclusion
- Histologically proven melanoma, must have 3 regional metastatic lesions that are in transit
Exclusion
- Central nervous system involvement by melanoma
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00116363
Start Date
March 1 2005
End Date
December 1 2006
Last Update
April 1 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030